The traditional FDA approval was supported by results from the Phase III APPLAUSE-IgAN study.

Novartis stock has delivered an 87.6% return over the past five years, yet its current valuation checks point to a mixed ...

Novartis (SWX:NOVN) is back in focus after the US Food and Drug Administration granted traditional approval for Fabhalta to ...

With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, ...

The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis’s oncology capabilities.

Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees pink slips.

ZURICH, July 6 (Reuters) - Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based ...

ADC payload with a differentiated mechanism of action; Combines oncology expertise of Novartis with Myricx Bio’s ...

With the latest layoffs, Novartis expects to let go of around 800 employees by the end of 2028. More than half of the cuts ...

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with s ...

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...

A warehouse fire at an 80-year-old Michigan craft supply company triggered 179 remote worker layoffs in New Jersey — one of ...